Dysregulated TGF-β Production Underlies the Age-Related Vulnerability to Chikungunya Virus
AuthorUhrlaub, Jennifer L.
DeFilippis, Victor R.
Streblow, Daniel N.
Coleman, Gary D.
Park, Byung S.
Lindo, John F.
Anzinger, Joshua J.
AffiliationUniv Arizona, Coll Med, Dept Immunobiol
Univ Arizona, Coll Med, Arizona Ctr Aging
MetadataShow full item record
PublisherPUBLIC LIBRARY SCIENCE
CitationDysregulated TGF-β Production Underlies the Age-Related Vulnerability to Chikungunya Virus 2016, 12 (10):e1005891 PLOS Pathogens
Rights© 2016 Uhrlaub et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractChikungunya virus (CHIKV) is a re-emerging global pathogen with pandemic potential, which causes fever, rash and debilitating arthralgia. Older adults over 65 years are particularly susceptible to severe and chronic CHIKV disease (CHIKVD), accounting for >90% of all CHIKV-related deaths. There are currently no approved vaccines or antiviral treatments available to limit chronic CHIKVD. Here we show that in old mice excessive, dysregulated TGF beta production during acute infection leads to a reduced immune response and subsequent chronic disease. Humans suffering from CHIKV infection also exhibited high TGF beta levels and a pronounced age-related defect in neutralizing anti-CHIKV antibody production. In vivo reduction of TGF beta levels minimized acute joint swelling, restored neutralizing antibody production and diminished chronic joint pathology in old mice. This study identifies increased and dysregulated TGF beta secretion as one key mechanism contributing to the age-related loss of protective anti-CHIKV-immunity leading to chronic CHIKVD.
NoteOpen Access Journal.
VersionFinal published version
SponsorsNIH [U54 AI081680]
- Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
- Authors: Arévalo MT, Huang Y, Jones CA, Ross TM
- Issue date: 2019 Apr
- Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.
- Authors: Her Z, Teng TS, Tan JJ, Teo TH, Kam YW, Lum FM, Lee WW, Gabriel C, Melchiotti R, Andiappan AK, Lulla V, Lulla A, Win MK, Chow A, Biswas SK, Leo YS, Lecuit M, Merits A, Rénia L, Ng LF
- Issue date: 2015 Jan
- A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
- Authors: Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, Himansu S, Diamond MS, Crowe JE Jr
- Issue date: 2019 May 17
- High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines.
- Authors: Yoon IK, Alera MT, Lago CB, Tac-An IA, Villa D, Fernandez S, Thaisomboonsuk B, Klungthong C, Levy JW, Velasco JM, Roque VG Jr, Salje H, Macareo LR, Hermann LL, Nisalak A, Srikiatkhachorn A
- Issue date: 2015 May
- A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
- Authors: Lam S, Nyo M, Phuektes P, Yew CW, Tan YJ, Chu JJ
- Issue date: 2015